At Nalu Bio, we learn from nature, and deliver through chemistry. Nalu Bio is creating a new category of cannabinoids and wellness ingredients that offer great therapeutic promise for more effective management of chronic pain and the treatment of opioid addiction. Nalu Bio's proprietary chemistry platform promises to set a new industry standard for purity, consistency, and quality, because it removes the risk of contamination from pesticides, heavy metals, and THC inherent in hemp extraction. Our unique, scalable platform has the ability to keep pace with anticipated market expansion, and will reliably deliver high quality and widely-accessible cannabinoids to global retail and pharmaceutical markets.
Shackelford Pharma Inc. is a biopharmaceutical company formed to develop medicines for neurological diseases with significant unmet patient needs. Founded by Dr. Alan Shackelford and leading medical industry executives, Shackelford Pharma is leveraging Dr. Shackelford’s real-world clinical experience to develop novel therapies for specific indications targeting the endocannabinoid system. Dr. Shackelford's work led to a heightened awareness, amongst physicians, patient groups and regulators of the potential for cannabinoid-based medicines to be used as a treatment for epilepsy and other significant unmet medical needs. Because of this increased awareness, patient groups, caregivers and physicians began to actively pursue opportunities to introduce cannabinoid-based treatment options, creating an environment in which it became possible to obtain the necessary FDA consents for cannabinoid drug development – a pathway GW Pharmaceuticals leveraged to commercialize Epidiolex, leading to $7.2B acquisition by Jazz Pharmaceuticals.